Boehringer Ingelheim Selects Medidata Clinical Cloud to Accelerate Innovation in Drug Development
Medidata announced that Boehringer Ingelheim has selected the Medidata Clinical Cloud to accelerate innovation across all of its drug development programs. The top-20 global pharmaceutical company will leverage Medidata’s technology platform to bring new insights and knowledge into multiple stages of the Boehringer Ingelheim drug development process, enabling its researchers to conduct faster, more accurate and more cost-effective clinical trials.
In supporting more than 10,000 clinical studies, 370,000 investigational sites and more than 2.7 million trial volunteers, the Medidata platform is driving a transformation in clinical trial design and execution, leading to better science and new medical breakthroughs for patients. Leveraging the power of this platform, Boehringer Ingelheim will integrate Medidata’s study planning, data management, data analytics and risk-based monitoring (RBM) capabilities into multiple stages of its drug development process.
“Boehringer Ingelheim creates therapeutic value through continuous innovation, so fortifying our R&D efforts with smart, agile technology is vital to our continued success,” said Klaus Stern, global head of Biostatistics & Data Sciences at Boehringer Ingelheim. “Medidata’s platform of cloud-based solutions and data analytics will increase the efficiency of our R&D and help us be more nimble in developing and conducting increasingly complex clinical trials. Ultimately, this can bring new medicines to patients sooner, which is what our team is working to do every day.”
Named one of Reuters’ top 100 global innovators in 2015, Boehringer Ingelheim has deep therapeutic expertise in oncology, immunology and respiratory diseases, cardiometabolic diseases, and diseases of the central nervous system. To enhance its portfolio of Phase I-III and post-approval studies, Boehringer Ingelheim is adopting the Medidata Clinical Cloud platform, including its solutions for electronic data capture, management and reporting (Medidata Rave); medical coding (Medidata Coder); safety reporting (Safety Gateway); trial design (Medidata Designer); and site budgeting and planning (Medidata Grants Manager). The Company will also use one of Medidata’s turnkey clinical analytics offerings (Medidata Insights), which provides advanced metrics, visualizations and the most powerful set of industry data and benchmarks. A phased rollout will begin in 2016.
Additionally, Boehringer Ingelheim will utilize solutions within Medidata RBM (including Medidata TSDV and Medidata SQM). These industry-leading tools for risk-based monitoring (RBM) will allow Boehringer Ingelheim to better prioritize resources around key areas of risk, such as patient safety and data quality and integrity. Boehringer Ingelheim has long been a proponent of RBM as a member of TransCelerate Biopharma, Inc. and as a representative within the non-profit’s risk-based monitoring work stream.
“Boehringer Ingelheim is committed to a faster and more flexible approach to R&D, and Medidata is excited to be a key partner in that effort for years to come,” said Medidata’s chief executive officer Tarek Sherif. “Our cloud technology and data-driven analytics deliver the features, the scale and the precise insights that Boehringer Ingelheim and a rapidly growing list of other global pharma companies need to develop exciting medical advances to improve people’s health and transform their lives.”